CTMP Activators
CTMP activators refer to a specialized group of chemical agents designed to modulate the activity of the protein carboxyl-terminal modulator protein (CTMP). CTMP is known to interact with various intracellular signaling pathways, notably those involving protein kinase B (PKB/Akt), a kinase that plays a critical role in diverse cellular processes such as glucose metabolism, cell proliferation, apoptosis, and transcription.
Activation of CTMP by these chemical agents can be accomplished through direct or indirect means. Direct activators might bind to CTMP and induce a structural conformation that enhances its ability to interact with its targets, such as Akt. By altering CTMP's conformation, these activators could potentiate its inhibitory effect on Akt, thereby modifying downstream signaling pathways. The enhancement of CTMP's activity could also result in the stabilization of its interaction with Akt or other associated proteins, leading to altered cellular responses to external stimuli. Indirect activators, in contrast, could act on the protein by influencing the cellular mechanisms that regulate CTMP expression, localization, or degradation. For instance, a chemical that upregulates the transcription of the CTMP gene would increase the protein's levels within the cell, thereby amplifying its activity. Alternatively, compounds that prevent the degradation of CTMP would also serve as indirect activators, preserving the protein's function and prolonging its effect on its target signaling pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that disrupts the PI3K/AKT pathway. By inhibiting PI3K, AKT phosphorylation is reduced, which can lead to activation of CTMP. CTMP is an AKT inhibitor, and when AKT activity is reduced, CTMP can become more active. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that indirectly influences CTMP's role in AKT regulation. Inhibition of mTOR can reduce AKT phosphorylation and thus increase the activity of CTMP. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol is known to activate SIRT1, which has been shown to deacetylate and activate LKB1. Activated LKB1 can then activate AMPK, which can inhibit mTOR, leading to a decrease in AKT activity. This indirectly enhances CTMP activity. | ||||||
Metformin-d6, Hydrochloride | 1185166-01-1 | sc-218701 sc-218701A sc-218701B | 1 mg 5 mg 10 mg | $292.00 $822.00 $1540.00 | 1 | |
Metformin activates AMPK, which inhibits mTOR, resulting in a decrease in AKT activity. This indirectly enhances CTMP activity. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Dorsomorphin is an AMPK inhibitor. Inhibition of AMPK can lead to activation of mTOR and thus increase AKT activity, which indirectly reduces CTMP activity. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR is an activator of AMPK. Activation of AMPK can inhibit mTOR, leading to a decrease in AKT activity. This indirectly enhances CTMP activity. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A-769662 is an activator of AMPK. Activation of AMPK can inhibit mTOR, leading to a decrease in AKT activity. This indirectly enhances CTMP activity. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $208.00 $270.00 | 29 | |
Akti-1/2 is a selective AKT inhibitor that reduces AKT phosphorylation and thus increases the activity of CTMP, which is an AKT inhibitor. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that can reduce ERK activity. Reduced ERK activity can lead to a decrease in mTOR activity, and thus a decrease in AKT activity. This indirectly enhances CTMP activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that disrupts the PI3K/AKT pathway. By inhibiting PI3K, AKT phosphorylation is reduced, which can lead to activation of CTMP. | ||||||